Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?

Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression re...

Descrición completa

Detalles Bibliográficos

Principais autores:	Warren Fingrut, Wendy Davis, Eric McGinnis, Karen Dallas, Khaled Ramadan, Hayley Merkeley, Heather Leitch, Yasser Abou Mourad, Ryan D. Cassaday, Camilla Ross, Chantal Léger
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2020-12-01
Series:	Current Oncology
Assuntos:	inotuzumab ozogamicin cd22 acute lymphoblastic leukemia flow cytometry immunotherapy
Acceso en liña:	https://www.mdpi.com/1718-7729/28/1/27
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!